WVE's Quality Score fell 1 point on Tue, Nov 10, to -7. It closed away from its high of the day (2 chart checks stopped).
Follow WVE's trial news. Pro members can get an alert when Wave Life Sciences files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 33% over three years while the S&P 500 rose 80%.
−3Long-term trend
| Holding it back | A $211M loss |
| Latest filing | 8-K, Oct 27 |
Thu Nov 12: Annual meeting11:30 AM ET. Directors, pay, auditor, stock plan.
After its last 4 reports it closed +5.2% on average, higher 3 of 4 times.
About 8 quarters
No shelf registration or at-the-market program on file in the last three years.
Director Adrian Rawcliffe sold 12,700 shares on Aug 12, under a planned sale. 10 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
WVE is #86 of 90 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 86 |
Sales over four quarters: WVE $70.9M, VKTX $0.
Reports Tue Nov 10, before the open (today). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $13.2M, 73% more than a year ago; a loss of $0.30 a share, from $0.32.
WVE's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“Wave expects that its current cash, cash equivalents, and marketable securities will be sufficient to fund operations into the third quarter of 2028.”
From its results filing (SEC filing · Oct 27)
Its share count grew 29% a year over 3 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 27, 2026 | +10.6% | +7.5% | +9.7% |
| Jul 30, 2026 | -3.3% | -0.9% | +2.1% |
| Apr 28, 2026 | +4.0% | +8.4% | +7.6% |
Sales grew in four of the last seven years, to $42.7M in 2025. It lost money in each of the eight years.
RSI 45.4, MACD above signal, below both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
“The biotechnology and pharmaceutical marketplace is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.”
WVE scores -7 today, which Breakaway calls Poor. It is #86 of 90 in Pharma by Quality Score, with 1 of 14 chart checks firing. Down 33% over three years while the S&P 500 rose 80%. Cash lasts about 8 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
WVE scores -7 today, which Breakaway calls Poor (below zero). That is #86 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind WVE's -7.
Reports Tue Nov 10, before the open, a date the company confirmed. WVE closed higher after 3 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.